| Please register to receive the benefits of our network-wide features. |
         Register (It's Free!) |
Log In
|
| Please register to receive the benefits of our network-wide features. |
Register (It's Free!) |
Log In
|
Robert Langer is one of the world’s most prolific, influential, and acclaimed social innovators of our time, and the full force of his impact will continue to affect the globe for generations to come. He has been referred to as “a medical pioneer in the guise of an engineer,” creating new science by revolutionizing the delivery of drugs and the engineering of human tissue. In this audio interview, Globeshakers host Tim Zak probes Langer's tenacious nature and perseverance in the face of public criticism and failed experiments. They discuss Langer's approach to controlled drug delivery systems, and his development of numerous cancer treatments at MIT's biomedical engineering labs.
Robert S. Langer is an institute professor at the Massachusetts Institute of Technology. He was formerly the Germeshausen Professor of Chemical and Biomedical Engineering and maintains activity in the departments of chemical engineering and the biological engineering division at MIT. Langer's contributions to medicine and the emerging fields of biotechnology are highly recognized and respected around the world. He is considered a pioneer of many new technologies, holds more than 500 granted or pending patents, and has authored more than 800 scientific papers. Langer received his bachelor's degree from Cornell University in chemical engineering. He earned his ScD in chemical engineering from MIT in 1974. From 1974-1977 he worked as a postdoctoral fellow for famed cancer researcher Judah Folkman at the Children's Hospital Boston and at Harvard Medical School. He has been an advisor to influential scholars in the fields of biomaterials, drug delivery systems, tissue engineering, and vascular medicine: W. Mark Saltzman, David J. Mooney, Lisa E. Freed, and Elazer R. Edelman.
Resources
This free podcast is from our Globeshakers series.
For The Conversations Network:
Play